Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | LDHB | P07195 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26967940 | 0.88 | KDM4E (0.39) | KDM4EUSP2KMT2AMEN1L3MBTL1 | |
| SCHEMBL70763 | 0.87 | KDM4E (0.46) | KDM4EUSP2KMT2AMEN1L3MBTL1 | |
| SCHEMBL25529107 | 0.85 | KMT2A (0.40) | KDM4EUSP2KMT2AMEN1L3MBTL1 | |
| SCHEMBL26967878 | 0.82 | KDM4E (0.42) | KDM4EUSP2KMT2AMEN1L3MBTL1 | |
| SCHEMBL26967868 | 0.82 | LDHA (0.41) | KDM4EUSP2ATMLDHALDHB | |
| SCHEMBL26967870 | 0.80 | GRIA4 (0.43) | KDM4EUSP2KMT2AMEN1L3MBTL1 | |
| SCHEMBL16731958 | 0.80 | USP2 (0.44) | KDM4EUSP2KMT2AMEN1L3MBTL1 | |
| SCHEMBL26967860 | 0.79 | MEN1 (0.36) | KDM4EUSP2KMT2AMEN1L3MBTL1 | |
| SCHEMBL7477443 | 0.78 | KDM4E (0.61) | KDM4EUSP2KMT2AMEN1L3MBTL1 | |
| SCHEMBL29868162 | 0.78 | POLB (0.41) | KDM4EUSP2KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158393-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS, INC. | 2024-05-16 | — | — | US | disclosed |
| EP-4294804-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | Exelixis, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158393-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, PLK2, MAP4K2 | KDM4E 2816/4885USP2 2894/4885KMT2A 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.